Investigation of Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (SRPT) Accused of Misleading Shareholders

According to the complaint for alleged violations of the Securities Exchange Act of 1934 between September 6, 2017 and August 19, 2019, in September 2017, Sarepta Therapeutics, Inc. (SRPT) announced positive results from its first-in-human study for the safety, tolerability, pharmacokinetics, and efficacy of its drug golodirsen.  Following these auspicious results, on February 14, 2019, Sarepta revealed that the FDA had accepted the company’s New Drug Application (“NDA”) “seeking accelerated approval for golodirsen and provided a regulatory action date of August 19, 2019,” failing to mention any possible or known risks related to golodirsen. Despite positive statements about the effects of golodirsen throughout the relevant period, on August 19, 2019, Sarepta revealed that a complete response letter from the FDA expressed concerns with (1) golodirsen’s risk of infection from its intravenous infusion ports, and (2) its renal toxicity seen in pre-clinical models. On this news, Sarepta’ stock price fell $18.24, or 15%, to close at $102.07.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

Name*
Ticker + Amount
This field is for validation purposes and should be left unchanged.